Back to results
US 2003/0195239 A1Published application
Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
AssigneePfizer Inc.
InventorsAllen J. Borchardt, Michael Paul Goble
Life of this patent
Estimating the term…
Abstract
Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus. 1
Claims13
A compound represented by formula (1):
- 59
- wherein:
- r is 0, 1, 2, 3, 4 or 5;
- Y is ═O or —O(CHm)n , where m is 2 or 3 and n is an integer from 0 to 5;
- X is
- 60
- when Y is —O(CHm)n and X is
- 61
- when Y is =O;
- or X and Y taken together form
- 62
- R1 is hydrogen, or an aryl, heteroaryl, or heterocycloalkyl group unsubstituted or substituted with one or more substituents selected from the group consisting of halogens;
- ═O;
- ═S;
- —CN;
- —NO2;
- alkyl;
- heteroalkyl;
- alkenyl;
- alkynyl;
- aryl;
- cycloalkyl;
- heterocycloalkyl;
- heteroaryl;
- alkoxy;
- —(CH2)zCN where z is an integer from 1 to 4;
- ═NH;
- —NHOH;
- —OH;
- —C(O)H;
- —OC(O)H;
- —C(O)OH;
- —OC(O)OH;
- —OC(O)OC(O)H;
- —OOH;
- —C(NH)NH2;
- —NHC(NH)NH2;
- —C(S)NH2;
- —NHC(S)NH2;
- —NHC(O)NH2;
- —S(O2)H;
- —S(O)H;
- —NH2;
- —C(O)NH2;
- —OC(O)NH2;
- —NHC(O)H;
- —NHC(O)OH;
- —C(O)NHC(O)H;
- —OS(O2)H;
- —OS(O)H;
- —OSH;
- —SC(O)H;
- —S(O)C(O)OH;
- —SO2C(O)OH;
- —NHSH;
- —NHS(O)H;
- —NHSO2H;
- —C(O)SH;
- —C(O)S(O)H;
- —C(O)S(O2)H;
- —C(S)OH;
- —C(SO)OH;
- —C(SO2)OH;
- —NHC(S)H;
- —OC(S)H;
- —OC(S)OH;
- —OC(SO2)H;
- —S(O2)NH2;
- —S(O)NH2;
- —SNH2;
- —NHCS(O2)H;
- —NHC(SO)H;
- —NHC(S)H;
- and —SH groups, unsubstituted or substituted with one or more substituents selected from the group consisting of halogens;
- ═O;
- ═S;
- —CN;
- —NO2;
- alkyl;
- heteroalkyl;
- alkenyl;
- alkynyl;
- aryl;
- cycloalkyl;
- heterocycloalkyl;
- heteroaryl;
- alkoxy;
- —(CH2)zCN where z is an integer from 1 to 4;
- ═NH;
- —NHOH;
- —OH;
- —C(O)H;
- —OC(O)H;
- —C(O)OH;
- —OC(O)OH;
- —OC(O)OC(O)H;
- —OOH;
- —C(NH)NH2;
- —NHC(NH)NH2;
- —C(S)NH2;
- —NHC(S)NH2;
- —NHC(O)NH2;
- —S(O2)H;
- —S(O)H;
- —NH2;
- —C(O)NH2;
- —OC(O)NH2;
- —NHC(O)H;
- —NHC(O)OH;
- —C(O)NHC(O)H;
- —OS(O2)H;
- —OS(O)H;
- —OSH;
- —SC(O)H;
- —S(O)C(O)OH;
- —SO2C(O)OH;
- —NHSH;
- —NHS(O)H;
- —NHSO2H;
- —C(O)SH;
- —C(O)S(O)H;
- —C(O)S(O2)H;
- —C(S)H;
- —C(SO)OH;
- —C(SO2)OH;
- —NHC(S)H;
- —OC(S)H;
- —OC(S)OH;
- —OC(SO2)H;
- —S(O2)NH2;
- —S(O)NH2;
- —SNH2;
- —NHCS(O2)H;
- —NHC(SO)H;
- —NHC(S)H;
- and —SH groups;
- and
- R2 is a cyclopentyl group, unsubstituted or substituted with one or more substituents selected from the group consisting of halogens;
- ═O;
- ═S;
- —CN;
- —NO2;
- alkyl;
- alkenyl;
- alkynyl;
- aryl;
- cycloalkyl;
- heterocycloalkyl;
- heteroaryl;
- —(CH2)zCN where z is an integer from 1 to 4;
- ═NH;
- —NHOH;
- —OH;
- —C(O)H;
- —OC(O)H;
- —C(O)OH;
- —OC(O)OH;
- —OC(O)OC(O)H;
- —OOH;
- —C(NH)NH2;
- —NHC(NH)NH2;
- —C(S)NH2;
- —NHC(S)NH2;
- —NHC(O)NH2;
- —S(O2)H;
- —S(O)H;
- —NH2;
- —C(O)NH2;
- —OC(O)NH2;
- —NHC(O)H;
- —NHC(O)OH;
- —C(O)NHC(O)H;
- —OS(O2)H;
- —OS(O)H;
- —OSH;
- —SC(O)H;
- —S(O)C(O)OH;
- —SO2C(O)OH;
- —NHSH;
- —NHS(O)H;
- —NHSO2H;
- —C(O)SH;
- —C(O)S(O)H;
- —C(O)S(O2)H;
- —C(S)OH;
- —C(SO)OH;
- —C(SO2)OH;
- —NHC(S)H;
- —OC(S)H;
- —OC(S)OH;
- —OC(SO2)H;
- —S(O2)NH2;
- —S(O)NH2;
- —SNH2;
- —NHCS(O2)H;
- —NHC(SO)H;
- —NHC(S)H;
- and —SH groups;
- and
- R3 is hydrogen, ═S, or SH unsubstituted or substituted with an aryl group;
- or a pharmaceutically acceptable salt or active metabolite thereof.
198 more elements
A compound selected from the group consisting of:
- 63 64 65
- or a pharmaceutically acceptable salt or active metabolite thereof.
A compound represented by formula (1):
- 66
- wherein:
- r is 0, 1 or 2;
- Y is ═O or —O(CHm)n , where m is 2 or 3 and n is an integer from 0 to 5;
- X is
- 67
- when Y is —O(CHm)n and X is
- 68
- when Y is ═O;
- or X and Y taken together form
- 69
- R1 is hydrogen, or an aryl, or heteroaryl, unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl;
- alkoxy;
- —OH;
- —NHC(O)H;
- and —SH groups, unsubstituted or substituted with one or more substituents selected from the group consisting of ═O;
- alkyl;
- and alkoxy groups;
- and
- R2 is a cyclopentyl group;
- and
- R3 is hydrogen;
- or a pharmaceutically acceptable salt or active metabolite thereof.
20 more elements
Dependencies are inferred from the claim text.